PO35DEMOGRAPHICS, TREATMENT AND OUTCOME FOR GLIOBLASTOMA MULTIFORME IN THE EAST MIDLANDS 2009-2013

Abstract

INTRODUCTION: A recent study (Brodbelt et al.) has assessed the incidence, treatment and survival of GBM nationally across the UK and by region, basing their case identification on from the National Cancer Registration Service and Hospital Episode Statistics. It is acknowledged that there are omissions from this data, so we sought in this study to evaluate the East Midlands regional incidence, primary treatments and survival of GBM patients, based on confirmed histopathological diagnoses. METHOD: The Neuropathology records for all patients undergoing Neurosurgery in the East Midlands were examined and all cases of GBM identified for the years 2009-13 inclusive. This data was then cross-referenced with hospital records to identify patient demographics, treatment received, overall survival and IDH-1 status. Statistical analysis was conducted using SPSS with all tests two tailed and significance taken at a p value of less than 0.05. RESULTS: 759 cases of histologically confirmed GBM were recorded in the East Midlands over the 5-year period. 60 of these had undergone previous surgery for a GBM or other intrinsic brain tumour, giving a new incidence rate of 3.87 / 100 000 / year. Median age at diagnosis was 63.2 years. 64% of patients underwent craniotomy and median overall survival was 7 months, increasing to 14 months in patients undergoing full radical treatment including temozolomide. 56.5% of patients received craniotomy, radiotherapy and temozolomide. CONCLUSION: Incidence rates, treatment protocols and survival are broadly equivalent between the national study and the East Midlands data. Both datasets demonstrate survival equivalent to the phase III trial data for good performance status patients.